Innate Pharma (IPH.PA) Stock Price

Innate Pharma Price

Euronext·CLOSED
2.19EUR+0.04 (+1.84 %)
Market closed

Revenue at Innate Pharma has contracted by 4.1% per year over the past 19 years to 2.79 M EUR. For Innate Pharma, the net margin of -1,764.5% is down versus -436.0% a few years ago. The consensus 12-month price target for Innate Pharma is 6.27 EUR, about 186.4% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 107% above its 52-week low.

Innate Pharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Innate Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Innate Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Innate Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Innate Pharma Stock Price History
DateInnate Pharma Price
8/13/20262.19 EUR
8/12/20262.15 EUR
8/11/20261.90 EUR
8/10/20261.83 EUR
8/7/20261.51 EUR
8/6/20261.52 EUR
8/5/20261.53 EUR
8/4/20261.53 EUR
7/31/20261.53 EUR
7/30/20261.56 EUR
7/29/20261.58 EUR
7/28/20261.62 EUR
7/27/20261.62 EUR
7/24/20261.59 EUR
7/23/20261.58 EUR
7/22/20261.56 EUR
7/21/20261.55 EUR
7/20/20261.50 EUR
7/17/20261.51 EUR
7/16/20261.56 EUR
7/15/20261.58 EUR
7/14/20261.59 EUR
7/13/20261.61 EUR
7/10/20261.57 EUR
7/9/20261.59 EUR
7/8/20261.59 EUR
7/7/20261.66 EUR
7/6/20261.71 EUR
7/3/20261.65 EUR
7/2/20261.60 EUR
7/1/20261.59 EUR
6/30/20261.62 EUR
6/29/20261.60 EUR
6/26/20261.58 EUR
6/25/20261.59 EUR
6/24/20261.66 EUR
6/23/20261.68 EUR
6/22/20261.61 EUR
6/19/20261.61 EUR
6/18/20261.60 EUR
6/17/20261.58 EUR
6/16/20261.55 EUR
6/15/20261.60 EUR
6/12/20261.56 EUR
6/11/20261.55 EUR
6/10/20261.54 EUR
6/9/20261.54 EUR
6/8/20261.55 EUR
6/5/20261.54 EUR
6/4/20261.55 EUR
6/3/20261.54 EUR
6/2/20261.57 EUR
6/1/20261.58 EUR
5/29/20261.61 EUR
5/28/20261.50 EUR
5/27/20261.54 EUR
5/26/20261.55 EUR
5/25/20261.61 EUR
5/22/20261.64 EUR
5/21/20261.80 EUR
5/20/20261.96 EUR
5/19/20261.81 EUR
5/18/20261.95 EUR
5/15/20261.74 EUR
5/14/20261.66 EUR
5/13/20261.23 EUR
5/12/20261.25 EUR
5/11/20261.26 EUR
5/8/20261.25 EUR
5/7/20261.26 EUR
5/6/20261.27 EUR
5/5/20261.23 EUR
5/4/20261.25 EUR
4/30/20261.20 EUR
4/29/20261.19 EUR
4/28/20261.18 EUR
4/27/20261.16 EUR
4/24/20261.12 EUR
4/23/20261.15 EUR
4/22/20261.18 EUR
4/21/20261.26 EUR
4/20/20261.30 EUR
4/17/20261.38 EUR
4/16/20261.35 EUR
4/15/20261.41 EUR
4/14/20261.36 EUR
4/13/20261.20 EUR
4/10/20261.16 EUR
4/9/20261.17 EUR
4/8/20261.19 EUR
4/7/20261.10 EUR
4/2/20261.16 EUR
4/1/20261.12 EUR
3/31/20261.06 EUR
3/30/20261.08 EUR
3/27/20261.10 EUR
3/26/20261.08 EUR
3/25/20261.15 EUR
3/24/20261.13 EUR
3/23/20261.17 EUR
3/20/20261.07 EUR
3/19/20261.15 EUR
3/18/20261.18 EUR
3/17/20261.17 EUR
3/16/20261.23 EUR
3/13/20261.25 EUR
3/12/20261.27 EUR
3/11/20261.35 EUR
3/10/20261.40 EUR
3/9/20261.38 EUR
3/6/20261.39 EUR
3/5/20261.37 EUR
3/4/20261.40 EUR
3/3/20261.37 EUR
3/2/20261.44 EUR
2/27/20261.46 EUR
2/26/20261.50 EUR
2/25/20261.49 EUR
2/24/20261.49 EUR
2/23/20261.41 EUR
2/20/20261.41 EUR
2/19/20261.45 EUR
2/18/20261.45 EUR
2/17/20261.44 EUR
2/16/20261.45 EUR
2/13/20261.47 EUR
2/12/20261.41 EUR
2/11/20261.40 EUR
2/10/20261.43 EUR
2/9/20261.40 EUR
2/6/20261.43 EUR
2/5/20261.49 EUR
2/4/20261.52 EUR
2/3/20261.52 EUR
2/2/20261.55 EUR
1/30/20261.55 EUR
1/29/20261.55 EUR
1/28/20261.51 EUR
1/27/20261.49 EUR
1/26/20261.50 EUR
1/23/20261.53 EUR
1/22/20261.56 EUR
1/21/20261.48 EUR
1/20/20261.52 EUR
1/19/20261.50 EUR
1/16/20261.51 EUR
1/15/20261.50 EUR
1/14/20261.51 EUR
1/13/20261.52 EUR
1/12/20261.55 EUR
1/9/20261.52 EUR
1/8/20261.53 EUR
1/7/20261.56 EUR
1/6/20261.55 EUR
1/5/20261.56 EUR
1/2/20261.62 EUR
12/31/20251.60 EUR
12/30/20251.61 EUR
12/29/20251.54 EUR
12/24/20251.55 EUR
12/23/20251.52 EUR
12/22/20251.56 EUR
12/19/20251.53 EUR
12/18/20251.55 EUR
12/17/20251.57 EUR
12/16/20251.61 EUR
12/15/20251.62 EUR
12/12/20251.63 EUR
12/11/20251.67 EUR
12/10/20251.64 EUR
12/9/20251.64 EUR
12/8/20251.66 EUR
12/5/20251.67 EUR
12/4/20251.68 EUR
12/3/20251.71 EUR
12/2/20251.74 EUR
12/1/20251.73 EUR
11/28/20251.75 EUR
11/27/20251.71 EUR
11/26/20251.66 EUR
11/25/20251.67 EUR
11/24/20251.64 EUR
11/21/20251.62 EUR
11/20/20251.60 EUR
11/19/20251.59 EUR
11/18/20251.55 EUR
11/17/20251.57 EUR
11/14/20251.59 EUR
11/13/20251.61 EUR
11/12/20251.66 EUR
11/11/20251.71 EUR
11/10/20251.87 EUR
11/7/20251.52 EUR
11/6/20251.51 EUR
11/5/20251.57 EUR
11/4/20251.61 EUR
11/3/20251.64 EUR
10/31/20251.67 EUR
10/30/20251.70 EUR
10/29/20251.73 EUR
10/28/20251.69 EUR
10/27/20251.89 EUR
10/24/20251.85 EUR
10/23/20251.82 EUR
10/22/20251.81 EUR
10/21/20251.80 EUR
10/20/20251.79 EUR
10/17/20251.84 EUR
10/16/20251.95 EUR
10/15/20251.87 EUR
10/14/20251.81 EUR
10/13/20251.68 EUR
10/10/20251.70 EUR
10/9/20251.81 EUR
10/8/20251.78 EUR
10/7/20251.73 EUR
10/6/20251.77 EUR
10/3/20251.82 EUR
10/2/20251.75 EUR
10/1/20251.74 EUR
9/30/20251.71 EUR
9/29/20251.64 EUR
9/26/20251.62 EUR
9/25/20251.62 EUR
9/24/20251.62 EUR
9/23/20251.59 EUR
9/22/20251.58 EUR
9/19/20251.58 EUR
9/18/20251.67 EUR
9/17/20251.76 EUR
9/16/20251.79 EUR
9/15/20251.82 EUR
9/12/20251.72 EUR
9/11/20251.77 EUR
9/10/20251.78 EUR
9/9/20251.77 EUR
9/8/20251.75 EUR
9/5/20251.77 EUR
9/4/20251.84 EUR
9/3/20251.86 EUR
9/2/20251.84 EUR
9/1/20251.88 EUR
8/29/20251.84 EUR
8/28/20251.86 EUR
8/27/20251.84 EUR
8/26/20251.86 EUR
8/25/20251.95 EUR
8/22/20252.01 EUR
8/21/20251.97 EUR
8/20/20251.98 EUR
8/19/20252.02 EUR
8/18/20251.99 EUR
Access this data via the Eulerpool API
Get Free API Key

Innate Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
51.90 M EUR
-12.67 M EUR
-7.57 M EUR
Jan 1, 2024
12.62 M EUR
-51.58 M EUR
-49.47 M EUR
Jan 1, 2025
2.79 M EUR
-53.43 M EUR
-49.18 M EUR
Jan 1, 2026 (e)
20.78 M EUR
-17.17 M EUR
-32.15 M EUR
Jan 1, 2027 (e)
32.47 M EUR
-26.84 M EUR
-39.72 M EUR
Jan 1, 2028 (e)
51.90 M EUR
-42.91 M EUR
-53.49 M EUR
Jan 1, 2029 (e)
268.70 M EUR
-222.14 M EUR
46.20 M EUR
Jan 1, 2030 (e)
529.10 M EUR
-437.41 M EUR
148.32 M EUR

Innate Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 11:25 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
17.0056.0032.0079.0068.0069.0012.0057.0051.0012.002.0020.0032.0051.00268.00529.00
–229.41-42.86146.88-13.921.47-82.61375.00-10.53-76.47-83.33900.0060.0059.38425.4997.39
-70.5912.50-106.2512.6633.8228.99-183.3310.539.80100.00100.00100.00100.00100.00100.00100.00
-12.007.00-34.0010.0023.0020.00-22.006.005.0012.002.0020.0032.0051.00268.00529.00
-10.007.00-47.005.00-27.001.00-47.00-57.00-12.00-51.00-53.00-17.00-26.00-42.00-222.00-437.00
-58.8212.50-146.886.33-39.711.45-391.67-100.00-23.53-425.00-2,650.00-85.00-81.25-82.35-82.84-82.61
-6.0012.00-48.003.00-20.00-63.00-52.00-58.00-7.00-49.00-49.00-32.00-39.00-53.0046.00148.00
-68.42-300.00-500.00-106.25-766.67215.00-17.4611.54-87.93600.00–-34.6921.8835.90-186.79221.74
53.6455.3354.7559.9565.7478.9979.5280.1980.5981.2591.4191.4191.4191.4191.4191.41
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Innate Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Innate Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Innate Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Innate Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Innate Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Innate Pharma stock margins

The Innate Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innate Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innate Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-184.12 %
-394.86 %
-436.01 %
Jan 1, 2022
10.42 %
-100.02 %
-100.74 %
Jan 1, 2023
10.83 %
-24.41 %
-14.59 %
Jan 1, 2024
100.00 %
-408.64 %
-391.97 %
Jan 1, 2025
100.00 %
-1,916.94 %
-1,764.51 %
Jan 1, 2026 (e)
100.00 %
-82.67 %
-154.76 %
Jan 1, 2027 (e)
100.00 %
-82.67 %
-122.33 %
Jan 1, 2028 (e)
100.00 %
-82.67 %
-103.07 %

Innate Pharma Stock Revenue, EBIT, Earnings per Share

The Innate Pharma earnings per share therefore indicates how much revenue Innate Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.15 EUR
-0.60 EUR
-0.66 EUR
Jan 1, 2022
0.72 EUR
-0.72 EUR
-0.72 EUR
Jan 1, 2023
0.64 EUR
-0.16 EUR
-0.09 EUR
Jan 1, 2024
0.16 EUR
-0.63 EUR
-0.61 EUR
Jan 1, 2025
0.03 EUR
-0.58 EUR
-0.54 EUR
Jan 1, 2026 (e)
0.26 EUR
-0.19 EUR
-0.40 EUR
Jan 1, 2027 (e)
0.40 EUR
-0.29 EUR
-0.49 EUR
Jan 1, 2028 (e)
0.64 EUR
-0.47 EUR
-0.66 EUR

Innate Pharma business model & stock analysis

The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company.

Innate Pharma SWOT Analysis

Strengths

1. Strong portfolio of innovative drug candidates.

2. Collaborative partnerships with renowned pharmaceutical companies.

3. Expertise in immuno-oncology, a rapidly growing field.

4. Solid financial position and resources for research and development.

Weaknesses

1. Limited commercialized products and dependence on partnerships.

2. Reliance on successful clinical trials for revenue generation.

3. Vulnerability to changes in regulations or intellectual property rights.

4. Lack of global market presence compared to larger pharmaceutical companies.

Opportunities

1. Rising demand for immunotherapies and targeted treatment options.

2. Potential for expansion into emerging markets with unmet medical needs.

3. Possibility of strategic partnerships for further drug development.

4. Increasing focus on personalized medicine and precision therapies.

Threats

1. Intense competition in the immuno-oncology sector.

2. Regulatory hurdles and approval challenges for new drugs.

3. Pricing pressures and reimbursement uncertainties.

4. Potential for disruptive technologies to replace current treatment approaches.

Innate Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Innate Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Innate Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Innate Pharma shares outstanding

The number of shares of Innate Pharma was 91.41 M in 2025. This indicates how many shares Innate Pharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
79.52 M Stocks
Jan 1, 2022
80.19 M Stocks
Jan 1, 2023
80.59 M Stocks
Jan 1, 2024
81.25 M Stocks
Jan 1, 2025
91.41 M Stocks
Jan 1, 2026 (e)
91.41 M Stocks
Jan 1, 2027 (e)
91.41 M Stocks
Jan 1, 2028 (e)
91.41 M Stocks

Current Innate Pharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
6.27
Last Price
2.19
Currency
EUR
12M Return Potential
186.44 %
LTM Return
0 %

Innate Pharma Analyst Rating Actions

DateFirmActionRatingReliability
9/17/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
6/15/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/14/2022
SVB Leerink
SVB Leerink
MaintainedOutperform–
9/15/2022
Citigroup
Citigroup
MaintainedBuy48
8/1/2022
SVB Leerink
SVB Leerink
MaintainedOutperform–
5/10/2022
SVB Leerink
SVB Leerink
MaintainedOutperform–
9/16/2021
SVB Leerink
SVB Leerink
MaintainedOutperform–
9/2/2021
SVB Leerink
SVB Leerink
UpgradeMarket PerformOutperform–
9/1/2021
SVB Leerink
SVB Leerink
UpgradeMarket PerformOutperform–
3/19/2021
SVB Leerink
SVB Leerink
MaintainedMarket PerformPerform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

EESG©

Eulerpool ESG Scorecard© for the Innate Pharma stock

53/100
58
Environment
49
Social
51
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Innate Pharma shareholder structure

% Name
11.33935%
Novo Nordisk Foundation
Novo Nordisk Foundation
10.29636%
Sanofi SA
Sanofi SA
9.03056%
Caisse des Dépôts et Consignations
Caisse des Dépôts et Consignations
0.64450%
CPR Asset Management
CPR Asset Management
0.25786%
Credit Mutuel Asset Management
Credit Mutuel Asset Management
0.12338%
Generali Insurance Asset Management S.p.A. SGR
Generali Insurance Asset Management S.p.A. SGR

Innate Pharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
75.1%
Float Shares
-
Shares Outstanding
-

Innate Pharma Executives and Management Board

17 members · avg. age 57 · 47 % women

SQ

Dr. Sonia Quaratino (62)

Executive Vice President, Member of the Executive Board, Chief Medical Officer, Member of the Leadership Team

770,500.00 EUR

Management

YM

Mr. Yannis Morel (51)

Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team

709,792.00 EUR
JD

Mr. Jonathan Dickinson (57)

Chief Executive Officer, Member of the Leadership Team

435,249.00 EUR
FL

Mr. Frederic Lombard (50)

Chief Financial Officer, Member of the Leadership Team

–
PV

Prof. Eric Vivier (60)

Senior Vice President, Chief Scientific Officer, Member of the Leadership Team

–
OL

Ms. Odile Laurent (63)

Vice President - Human Resources, Member of the Leadership Team

–
HW

Mr. Henry Wheeler (42)

Vice President - Investor Relations and Communications, Member of the Leadership Team

–

Board of Directors

IS

Dr. Irina Staatz-Granzer (65)

Chairwoman of the Board of Directors · since 2009

100,000.00 EUR
PB

Ms. Pascale Boissel (58)

Independent Vice Chairwoman of the Supervisory Board · since 2020

64,000.00 EUR
VC

Ms. Veronique Chabernaud (63)

Independent Member of the Supervisory Board

53,000.00 EUR
SB

Dr. Sally Bennett (53)

Independent Member of the Supervisory Board

52,000.00 EUR
PB

Prof. Jean-Yves Blay (64)

Independent Member of the Supervisory Board

34,000.00 EUR
GB

Mr. Gilles Brisson (73)

Member of the Supervisory Board · since 2007

29,000.00 EUR

Frequently asked questions about Innate Pharma

The business model of Innate Pharma SA is centered around the development and commercialization of innovative immunotherapies for the treatment of cancer and inflammatory diseases. Innate Pharma combines cutting-edge expertise in immunology with advanced technology platforms to discover and develop first-in-class antibodies targeting receptors and pathways controlling the activation and regulation of the immune system. By leveraging its scientific know-how and strategic partnerships, Innate Pharma aims to bring novel immunotherapies to patients, addressing unmet medical needs and potentially improving outcomes. Innate Pharma SA focuses on research, development, and collaboration to advance its pipeline and ultimately deliver breakthrough therapies.

Innate Pharma SA is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Innate Pharma SA in the market include larger biopharmaceutical companies such as Bristol-Myers Squibb, Amgen, and Novartis. They operate in the same industry and compete for similar market segments and resources. These competitors pose a challenge to Innate Pharma SA as they have strong financial capabilities, established market presence, and a diverse product pipeline. Innate Pharma SA, however, differentiates itself through its innovative drug discovery platforms and focuses on developing immune-based therapies for the treatment of cancer and inflammatory diseases.

Innate Pharma SA is a biotechnology company based in Marseille, France. Founded in 1999, the company focuses on developing innovative immunotherapies for the treatment of cancer and inflammatory diseases. Innate Pharma is committed to harnessing the power of the innate immune system to fight against diseases. The company has a strong track record in the field of antibody-based therapies and has established strategic partnerships with leading pharmaceutical companies for the development and commercialization of its products. Innate Pharma SA has a dedicated team of scientists and researchers working towards advancing the understanding and application of immunotherapies for improved patient outcomes.

Innate Pharma SA has achieved significant milestones in its journey. The company has successfully developed innovative therapies in the field of immuno-oncology. Innate Pharma SA collaborated with leading pharmaceutical companies, such as AstraZeneca and Novo Nordisk, for the clinical development of its products. Additionally, the company has made remarkable progress in advancing its pipeline, including the advancement of its lead product candidate, monalizumab, into clinical trials for various cancer indications. Innate Pharma SA has also secured a strong intellectual property portfolio to protect its cutting-edge technologies and remains committed to revolutionizing the treatment of cancer and other diseases.

Innate Pharma SA is primarily present in various countries and regions around the world. The company has a global presence with a focus on key markets including the United States, Europe, and Asia. Innate Pharma SA has established its presence in the United States through its subsidiary, Innate Pharma US Inc., which is located in Rockville, Maryland. In Europe, the company has a strong presence in France, its home country, as well as in other European countries. Additionally, Innate Pharma SA has been expanding its reach in the Asian market, particularly in Japan and China.

Innate Pharma SA represents values of innovation, collaboration, and patient focus. The company is committed to advancing the field of immuno-oncology through its pioneering research and development efforts. Innate Pharma SA believes in working closely with partners and leveraging their expertise to accelerate the discovery of new therapeutic solutions. With a strong focus on addressing unmet medical needs, Innate Pharma SA aims to improve patient outcomes and make a difference in the fight against cancer. By combining cutting-edge science with a patient-centric approach, the company strives to bring innovative and effective treatments to market.

Analysts currently set an average price target of 6.27 EUR for the Innate Pharma stock (median: 6.27 EUR), implying +186.4 % versus the latest price. The consensus is based on 8 analyst ratings.

Innate Pharma Analyst Price Targets 2026

8 analysts currently rate the Innate Pharma stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Innate Pharma to generate revenue of 20.78 M EUR and earnings per share of -0.35 EUR.

Innate Pharma Analyst Price Targets 2026

The Innate Pharma share (IPH.PA) is listed on 7 stock exchanges, including: Frankfurt (IDD.F), München (IDD.MU), Düsseldorf (IDD.DU), London (0EVI.L), Paris (IPH.PA).

Innate Pharma SA is a biopharmaceutical company specializing in the research and development of immunoncology therapies. The company is headquartered in Marseille, France, with subsidiaries in the United States and Switzerland. Innate Pharma SA's business model focuses on the identification and development of novel target molecules and compounds with therapeutic potential in cancer and other immune system diseases. The company has an extensive portfolio of proprietary technologies and platforms that allow for the discovery and development of innovative therapies. One of Innate Pharma SA's core competencies is the discovery and characterization of natural killer cells (NK cells), an important type of immune cell responsible for defending against cancer cells and viral infections. The company specializes in the development of NK cell-based immunotherapies aimed at mobilizing the immune system to fight cancer cells. Innate Pharma SA currently offers several products and therapies in various stages of clinical development. One important product is Monalizumab, a monoclonal antibody aimed at reducing immune suppression in tumors and promoting the activation of T cells and NK cells. Monalizumab is currently in a Phase III study for the treatment of head and neck squamous cell carcinomas. Another important product from Innate Pharma SA is IPH4102, a monoclonal antibody targeting CD47, a molecule overexpressed by cancer cells. IPH4102 has the potential to recognize and destroy cancer cells by promoting the engulfment of cancer cells by macrophages. The drug is currently in a Phase II study for the treatment of T-cell lymphomas. Innate Pharma SA also has a pipeline of promising NK cell-based immunotherapies in clinical development, including a bispecific antibody targeting CD16 and CD19, and a recombinant interleukin-15 protein that promotes the proliferation and activation of NK cells. Additionally, Innate Pharma SA has entered into a strategic partnership with AstraZeneca plc to advance the development and commercialization of Lumoxiti (Moxetumomab pasudotox), an FDA-approved antibody therapy used for the treatment of hairy cell leukemia. Innate Pharma SA primarily funds its business through private and public financing, including investments from venture capital firms and government research grants. The company has also established successful partnerships with other leading biopharmaceutical companies such as Bristol-Myers Squibb and Novo Nordisk to develop innovative immunoncology therapies. In summary, Innate Pharma SA's business model is based on the identification and development of novel immunoncology therapies, particularly NK cell-based immunotherapies. The company has an extensive portfolio of proprietary technologies and platforms that allow for the discovery and development of innovative therapies. Innate Pharma SA currently offers several products and therapies in various stages of clinical development, including Monalizumab, IPH4102, and other promising NK cell-based immunotherapies.

The expected revenue of Innate Pharma is 20.78 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Innate Pharma is -32.15 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Innate Pharma is currently -6.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Innate Pharma stock.

The price-to-sales ratio (P/S) of Innate Pharma is currently 9.64. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Innate Pharma stock.

The Eulerpool Quality Score for Innate Pharma is 1/10.

The ISIN of Innate Pharma is FR0010331421. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Innate Pharma is A0LCUJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Innate Pharma is IPH.PA. The ticker symbol is used to trade Innate Pharma shares on the stock exchange.

Innate Pharma paid dividends every year for the past 0 years.

Innate Pharma is assigned to the 'Health' sector.

The dividends of Innate Pharma are distributed in EUR.

All fundamentals and in-depth analysis of Innate Pharma

Our stock analysis for Innate Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innate Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Innate Pharma Stock
Innate Pharma Revenue→
Innate Pharma Stock
Innate Pharma Net Income→
Innate Pharma Stock
Innate Pharma P/E→
Innate Pharma Stock
Innate Pharma P/S→
Innate Pharma Stock
Innate Pharma EBIT→
Innate Pharma Stock
Innate Pharma Dividend→
Innate Pharma Stock
Innate Pharma Directors Dealings→
Innate Pharma Stock
Innate Pharma Stocks→
Innate Pharma Stock
Innate Pharma Market capitalization→
Innate Pharma Stock
Innate Pharma Debt→
Innate Pharma Stock
Innate Pharma Liabilities→
Innate Pharma Stock
Innate Pharma Equity→
Innate Pharma Stock
Innate Pharma AAQS→
Innate Pharma Stock
Innate Pharma Employees→
Innate Pharma Stock
Innate Pharma ROE→
Innate Pharma Stock
Innate Pharma ROA→
Innate Pharma Stock
Innate Pharma ROCE→
Innate Pharma Stock
Innate Pharma News→
Innate Pharma Stock
Innate Pharma Analyst Price Targets→

Health Stocks

Inner Mongolia Furui Medical Science CoInnate PharmaInnoCare PharmaINmune BioInnoCare PharmaInmodeInnopharmaxInMed PharmaceuticalsInnova CaptabINKON Life Technology CoInnovAge HoldingInitiator Pharma A/SAll Stocks A–Z →